Harbinger Health presented new research at the American Association for Cancer Research (AACR) Annual Meeting showcasing advancements in their multi-cancer early detection (MCED) blood tests. These advancements involve a new analytical framework for assessing test performance and an enhanced laboratory methodology to improve accuracy. The company aims to improve early cancer detection and impact cancer screening, diagnosis, and management.
This research is vital because it addresses the urgent need for more effective and accurate early cancer detection methods. Current methods are often limited in scope, detecting only one cancer at a time, or lack the precision necessary for impactful clinical decisions. Harbinger’s work, particularly with a focus on improved specificity and predictive value, could lead to earlier intervention and better outcomes for patients across various cancer types. The emphasis on clinically meaningful metrics, as opposed to solely focusing on sensitivity and specificity, provides clinicians with more actionable information for patient care.
The novel methodology, utilizing a two-tiered system combining a cfDNA-based machine learning classifier (MLX) and a patient-specific intra-individual classifier (IIX), achieved a specificity of 99.89% and a positive predictive value (PPV) of 80.7% in some scenarios. Their new analytical framework applied to data from the CORE-HH study showed a specificity of 98.6% and highlighted the test’s potential for cancers currently lacking effective screening programs, such as pancreaticobiliary and hepatobiliary cancers. Certain cancers, including upper gastrointestinal, colorectal, and hepatobiliary, demonstrated high PPVs, indicating a higher probability of true positives and a more favorable risk-benefit profile for patients.
These findings suggest a potential shift in the early cancer detection landscape. Harbinger Health’s focus on developing tests with high specificity and PPV, along with a framework to quantify clinically relevant performance metrics, could lead to more accurate diagnoses and more effective treatment strategies. This advancement holds promise for improving patient outcomes and transforming the approach to cancer screening and management.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
